Neurocrine Biosciences Balance Sheet
NASDAQ: NBIXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Neurocrine Biosciences financial position
At the end of fiscal 2025, Neurocrine Biosciences reported total assets of $4.63 billion, up 24.5% from a year earlier against total liabilities of $1.38 billion. Shareholders' equity stood at $3.25 billion, or 70.2% of assets. The company held $713.0 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 3.39, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Neurocrine Biosciences balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 713.00M | 233.00M | 251.10M | 262.90M | 340.80M | 187.10M | 112.30M | 141.71M | 254.71M | 83.27M |
| Short-Term Investments | 767.40M | 843.10M | 780.50M | 726.40M | 370.50M | 613.90M | 558.20M | 509.20M | 261.22M | 224.08M |
| Receivables | 686.80M | 479.10M | 439.30M | 350.00M | 185.50M | 157.10M | 126.60M | 57.41M | 31.13M | 0 |
| Inventory | 69.00M | 57.40M | 38.30M | 35.10M | 30.50M | 28.00M | 17.30M | 10.86M | 1.02M | 0 |
| Total Current Assets | 2.52B | 1.72B | 1.61B | 1.45B | 972.80M | 1.02B | 831.00M | 737.78M | 554.92M | 310.44M |
| Property, Plant & Equipment | 89.80M | 82.60M | 70.80M | 58.60M | 58.60M | 44.60M | 41.90M | 33.87M | 10.81M | 6.27M |
| Goodwill | 6.10M | 5.70M | 5.80M | 5.40M | 0 | — | — | — | — | — |
| Intangible Assets | 4.70M | 36.50M | 35.50M | 37.20M | 0 | — | — | — | — | — |
| Long-Term Investments | 1.06B | 739.50M | 687.50M | 299.40M | 560.70M | 227.10M | 299.70M | 216.03M | 247.36M | — |
| Total Assets | 4.63B | 3.72B | 3.25B | 2.37B | 2.07B | 1.73B | 1.31B | 993.15M | 817.59M | 365.09M |
| Accounts Payable | 674.30M | 461.60M | 448.80M | 347.60M | 225.80M | 168.70M | 141.30M | 13.80M | 5.65M | 5.08M |
| Total Current Liabilities | 743.40M | 507.70M | 654.80M | 537.70M | 245.80M | 186.50M | 565.30M | 88.23M | 54.43M | 30.41M |
| Total Liabilities | 1.38B | 1.13B | 1.02B | 660.90M | 698.50M | 608.50M | 669.10M | 512.39M | 445.45M | 50.21M |
| Shareholders' Equity | 3.25B | 2.59B | 2.23B | 1.71B | 1.37B | 1.13B | 636.90M | 480.80M | 372.20M | 314.88M |
| Retained Earnings | 447.70M | 29.20M | -157.10M | -406.80M | -635.80M | -725.40M | -1.13B | -1.18B | -1.20B | -1.06B |
| Net Cash (Debt) | 1.48B | 1.08B | 1.03B | 989.30M | 711.30M | 801.00M | 670.50M | 650.91M | 515.93M | 307.35M |
| Shares Outstanding | 100.10M | 99.40M | 98.70M | 96.50M | 94.90M | 93.50M | 92.30M | 90.80M | 88.79M | 86.88M |
This table shows 10 annual periods of Neurocrine Biosciences's balance sheet, from FY 2025 back to FY 2016, across 17 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow NBIX's reporting calendar. What is a balance sheet?